![](https://news.europawire.eu/wp-content/uploads/2021/08/Roche-FACADE-144x144.jpg)
(IN BRIEF) Roche has received approval from the European Commission for PiaSky® (crovalimab), a novel treatment for paroxysmal nocturnal haemoglobinuria (PNH), making it the first monthly subcutaneous (SC) treatment available in the European Union. PiaSky, which can be self-administered by … Read the full press release